HI
CLLS

HBK Investments’s Cellectis CLLS Stock Holding History

HBK Investments’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,633
Closed -$272K – 1218
2018
Q3 		$272K Sell
9,633
-33,429
-78% -$960K ﹤0.01% 1073
2018
Q2 		$1.22M Buy
43,062
+4,924
+13% +$147K 0.01% 597
2018
Q1 		$1.2M Buy
38,138
+21,038
+123% +$665K 0.01% 583
2017
Q4 		$498K Buy
+17,100
New +$466K ﹤0.01% 746
2016
Q1 		– Sell
-15,675
Closed -$486K – 974
2015
Q4 		$486K Buy
+15,675
New +$476K ﹤0.01% 760

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBK Investments's CLLS Position: Q4 2018 in Review

HBK Investments sold out of Cellectis (CLLS) in Q4 2018, closing a stake of 9,633 shares — an estimated $272K sold.

HBK Investments first reported a position in CLLS in Q4 2015 and held it in 5 quarters. The position peaked at $1.22M in Q2 2018. 65 funds tracked by Wall St. Rank hold CLLS as of Q4 2018.

  • HBK Investments reported no remaining Cellectis position as of Q4 2018 after selling out during the quarter.
  • HBK Investments sold 9,633 Cellectis shares in Q4 2018, an estimated $272K.
  • HBK Investments first reported a position in Cellectis in Q4 2015 and held it in 5 quarters.
  • HBK Investments's Cellectis position peaked at $1.22M in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Cellectis as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.